10-Q: Inari Medical Reports First Quarter 2024 Results with Revenue Growth and Increased Net Loss

Inari Medical's first quarter 2024 results show a revenue increase of 23.3% year-over-year, but also a significant increase in net loss.

Summary

• Inari Medical reported a revenue of $143.2 million for the first quarter of 2024, a 23.3% increase compared to $116.2 million in the same period of 2023.
• The company's gross margin decreased slightly to 86.8% from 88.2% year-over-year.
• Operating expenses increased significantly, driven by higher selling, general, and administrative costs, as well as research and development expenses.
• The company's net loss for the quarter was $24.2 million, a substantial increase from the $2.2 million loss in the first quarter of 2023.
• The increase in net loss was primarily due to increased operating expenses, including a $6.3 million change in fair value of contingent consideration, $2.5 million in amortization of intangible assets, and $2.8 million in acquisition-related expenses.
• The company had $66.7 million in cash and cash equivalents, $0.5 million in restricted cash, and $34.6 million in short-term investments as of March 31, 2024.
• Inari Medical has a credit facility with Bank of America with approximately $59.8 million available for borrowing as of March 31, 2024.

Sentiment

Score: 5

Explanation: The document presents mixed signals. While revenue growth is strong, the significant increase in net loss and the ongoing legal investigation temper the positive aspects. The company's future success depends on managing expenses and resolving the legal issues.

Positives

• The company experienced a significant increase in revenue, demonstrating strong sales growth.
• The company continues to expand its sales territories and customer base.
• The company has a strong cash position and access to a credit facility.

Negatives

• The company's net loss increased substantially year-over-year.
• Operating expenses increased significantly, impacting profitability.
• Gross margin decreased slightly, indicating potential cost pressures.
• The company is facing a civil investigation from the U.S. Department of Justice.

Risks

• The company's future performance is subject to risks outlined in their annual report.
• The company is involved in a civil investigation by the U.S. Department of Justice, which could have a material impact on the business.
• The company's ability to achieve future profitability is dependent on managing operating expenses and maintaining revenue growth.
• The company's contingent consideration liability related to the LimFlow acquisition could require significant cash payments in the future.
• The company's reliance on a credit facility exposes it to potential risks related to debt financing.

Future Outlook

The company expects revenue to increase as they expand their offerings, grow the sales organization, add customers, and expand physician awareness and usage of their products. They also anticipate that their cash and cash equivalents, short-term investments, and available borrowings will be sufficient to fund their operating expenses for at least the next 12 months.

Management Comments

• The company is committed to improving lives by creating innovative solutions for unmet health needs.
• The company is passionate about establishing their treatments as the standard of care for venous disease and other disease states.
• The company believes their mission-focused and highly-trained commercial organization provides a significant competitive advantage.

Industry Context

The company operates in the medical device industry, specifically focusing on minimally invasive thrombectomy devices. The acquisition of LimFlow expands their reach into limb salvage for patients with chronic limb-threatening ischemia, a growing area of need. The company's growth is tied to the adoption of their products by hospitals and physicians, and their ability to expand into new markets and disease states.

Comparison to Industry Standards

• Inari Medical's revenue growth of 23.3% is strong compared to the overall medical device industry, which typically sees single-digit growth rates.
• However, the significant increase in net loss is a concern, as many medical device companies aim for profitability or at least reduced losses at this stage of growth.
• Companies like Penumbra, which also focuses on thrombectomy devices, have shown similar revenue growth but have been more successful in managing operating expenses and achieving profitability.
• The gross margin of 86.8% is relatively high for the medical device industry, indicating strong pricing power, but the slight decrease suggests potential cost pressures.
• The company's investment in R&D is in line with industry standards for companies focused on innovation and new product development.
• The contingent consideration liability related to the LimFlow acquisition is a unique factor that could impact the company's financial performance compared to peers.

Legal Proceedings

• The company received a civil investigative demand from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.
• The investigation primarily relates to meals and consulting service payments provided to health care professionals.
• The company is cooperating with the investigation.

Related Party Transactions

• The company utilizes MRI The Hoffman Group, a recruiting services company owned by the brother of the former CEO and current board member.
• The company paid MRI $10,000 for recruiting services in the three months ended March 31, 2024.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the ongoing legal investigation.
• Employees may be impacted by the company's performance and any potential changes resulting from the legal investigation.
• Customers may benefit from the company's continued product development and expansion.
• Suppliers may see increased business as the company grows.
• Creditors may be impacted by the company's financial performance and any potential changes to their credit facility.

Next Steps

• The company plans to continue expanding its sales force and territories.
• The company will continue to develop new products and enhance existing ones.
• The company will continue to advance research and development, including clinical study activities.
• The company will continue to evaluate the impact of the Organisation for Economic Co-operation and Developments Base Erosion and Profit Shifting Two-Pillar on their consolidated financial statements.

Key Dates

Keywords

Inari Medical, thrombectomy, medical devices, venous thromboembolism, VTE, LimFlow, chronic limb-threatening ischemia, CLTI, revenue, net loss, financial results, operating expenses, credit facility, acquisition